Safe Harbor Loci for Stable Transgene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene editing therapies face challenges such as poor knock-in efficiency, insertional oncogenesis, unstable transgene expression, and off-target effects due to random integration of viral vectors, necessitating the identification of safe harbor loci for targeted transgene insertion in cancer immunotherapy.
Innovation Solution
Identification and utilization of specific safe harbor loci, such as those on chromosomes 10, 11, 15, and 16, and integration sites like GS94 and GS102, for efficient insertion and stable expression of transgenes in T cells, using CRISPR-Cas9 technology with guide RNAs and Cas9 endonucleases, linked to endogenous or exogenous promoters like EF1a.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If viral vectors are used for gene delivery, then transgene delivery is achieved, but random integration causes insertional oncogenesis and off-target effects
Solution Approach 1:
The patent identifies and characterizes safe harbor loci in advance through systematic screening of chromosomal regions for their ability to support stable transgene expression without causing insertional oncogenesis. These pre-validated loci are then used as target sites for CRISPR-Cas9 mediated integration, eliminating the need for random integration and preventing off-target effects before therapy implementation.
Solution Approach 2:
The patent introduces CRISPR-Cas9 technology as an intermediary mechanism to guide viral vector integration to specific safe harbor loci. The guide RNA and Cas9 endonuclease complex acts as a mediator that directs the integration process to predetermined safe sites, replacing random integration and ensuring precise, controlled transgene insertion that maintains genomic stability.
2Productivity
If CRISPR-Cas9 is used for targeted integration, then knock-in efficiency is improved, but off-target effects may occur
Solution Approach 1:
The patent applies local quality by designing guide RNAs with high specificity for particular safe harbor loci sequences. The guide RNA sequences are optimized to match only the intended target sites with perfect complementarity, while having minimal homology to other genomic regions. This localized specificity ensures that CRISPR-Cas9 editing occurs only at the desired safe harbor loci, maintaining high knock-in efficiency while preventing off-target effects.
3Ease of manufacture
If transgenes are integrated at random locations, then integration simplicity is maintained, but transgene expression becomes unstable
Solution Approach 1:
The patent performs preliminary identification and validation of safe harbor loci that are known to support stable transgene expression. These loci are pre-screened for characteristics such as open chromatin structure, active transcriptional environment, and absence of position effects. By integrating transgenes at these pre-validated sites through CRISPR-Cas9, the patent achieves both controlled integration and stable, long-term transgene expression without the simplicity compromises of random integration.
Data Source
AI summary
Provided herein are safe harbor loci and methods for identifying and using safe harbor loci to engineer cells to express transgenes. The safe harbor loci exhibit increased transgene knock-in efficiency and allow for increased, stable expression of transgenes in engineered cells. Guide ribonucleic acids (gRNAs) may be used for insertion of transgenes in the safe harbor loci.